ArticleCurrent cancer drug targets2026
MiR-124-3p Suppresses Glioma Cells Progression by Targeting STAT3/NAMPT and Inhibiting AKT/ERK Signaling.
Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated network toxicology, bioinformatics, and molecular docking reveal the potential molecular mechanisms linking bisphenol A to glioma progression.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn our preliminary study, bioinformatics analyses identified differentially expressed miRNAs and mRNAs in glioma versus peritumoral samples, with functional validation of multiple miRNA-mRNA regulatory axes. MicroRNA-124-3p (miR-124-3p)/nicotinamide phosphoribosyltransferase (NAMPT) was among these axes and may critically regulate glioma malignant phenotypes, and this study aimed to validate their regulatory interactions.
methodsWe analyzed NAMPT expression in glioma tissues using clinical datasets from the Chinese Glioma Genome Atlas (CGGA). Functional effects of miR-124-3p and NAMPT were evaluated in U87 and U251 glioma cells using quantitative real-time PCR (qRT-PCR), Western blotting, colony formation assays, CCK-8 cell viability assays, Transwell invasion assays, and flow cytometry. The direct interaction between miR-124-3p and NAMPT was investigated using dual-luciferase reporter assays.
resultsClinical data revealed that elevated NAMPT expression correlated with poor prognosis, advanced pathological grade, and IDH-wild-type gliomas. MiR-124-3p overexpression significantly inhibited glioma cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, miR-124-3p downregulated NAMPT expression through regulation, leading to suppression of the p-AKT and p-ERK signaling pathways. Notably, NAMPT overexpression rescued the tumor-suppressive effects of miR-124-3p, confirming its critical role in this axis. However, dual-luciferase reporter assays ruled out a direct interaction between miR-124-3p and the NAMPT transcript, suggesting an indirect regulatory mechanism. Further investigation through WB and rescue experiments identified the transcription factor STAT3 as the key intermediary, serving as a functional bridge linking miR-124-3p to the regulation of NAMPT expression. DISCUSSION: Accumulating evidence demonstrates that miR-124-3p functions as a potent tumor suppressor across diverse malignancies through distinct molecular mechanisms. STAT3, which is directly targeted by miR-124-3p, serves as the functional bridge linking miR-124-3p to NAMPT regulation. NAMPT, as a critical node in the NAD⁺ biosynthetic pathway, influences the malignant biological behavior of glioma through downstream PI3K/AKT and MEK/ERK signaling transduction pathways.
conclusionMiR-124-3p functions as a tumor suppressor in glioma by repressing STAT3/NAMPT-mediated AKT/ERK signaling, highlighting its potential as a diagnostic biomarker and therapeutic target for glioma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.